Clinical Trial

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Study acronym: ALDP001
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
Trial Details
NCT Number NCT07219849
Lead Sponsor Alixer Nexgen Therapeutics Limited
Conditions Seasonal Allergic Rhinitis (SAR)
Enrollment 164 participants
Start Date 2025-10-17
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-10-22